Kezar Life Sciences Completes Acquisition by Aurinia Pharmaceuticals, Delists from Nasdaq
Summary
Kezar Life Sciences, Inc. has been acquired by Aurinia Pharma U.S., Inc. for $6.955 per share in cash plus one Contingent Value Right, marking its transition to a wholly-owned subsidiary and delisting from Nasdaq.
Key Events
-
Merger Completion
Aurinia Pharma U.S., Inc. successfully completed its tender offer and merged with Kezar Life Sciences on May 11, 2026, making Kezar a wholly-owned subsidiary.
-
Offer Terms Finalized
Shareholders received $6.955 per share in cash plus one Contingent Value Right (CVR) for each share tendered. In-the-money options were converted to cash and CVRs, while out-of-money options were cancelled.
-
Delisting from Nasdaq
Kezar's common stock will be delisted from The Nasdaq Stock Market LLC, and its registration under the Exchange Act will be terminated, effective May 11, 2026.
-
Board and Management Changes
The entire board of directors resigned, and the previous executive officers' employment terminated. New directors and officers from Aurinia's Merger Sub were appointed to the surviving corporation.
Analysis
This 8-K confirms the successful completion of the tender offer and subsequent merger, finalizing the acquisition of Kezar Life Sciences by Aurinia Pharmaceuticals. The company's common stock will be delisted from Nasdaq, and its registration terminated, effectively ending its life as an independent public entity. All outstanding shares have been converted into the offer price, and the board and executive team have been replaced. This is the final step in a process initiated on March 30, 2026, with the definitive merger agreement, and followed by the tender offer commencement on April 13, 2026.
At the time of this filing, KZR was trading at $7.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.9M. The 52-week trading range was $3.53 to $7.55. This filing was assessed with neutral market sentiment and an importance score of 10 out of 10.